Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.08
MDSO's Cash to Debt is ranked higher than
56% of the 2078 Companies
in the Global Health Information Services industry.

( Industry Median: 5.21 vs. MDSO: 1.08 )
MDSO' s 10-Year Cash to Debt Range
Min: 0.4   Max: No Debt
Current: 1.08

Equity to Asset 0.42
MDSO's Equity to Asset is ranked higher than
52% of the 2008 Companies
in the Global Health Information Services industry.

( Industry Median: 0.60 vs. MDSO: 0.42 )
MDSO' s 10-Year Equity to Asset Range
Min: -1.75   Max: 0.67
Current: 0.42

-1.75
0.67
Interest Coverage 4.03
MDSO's Interest Coverage is ranked lower than
57% of the 1364 Companies
in the Global Health Information Services industry.

( Industry Median: 2350.48 vs. MDSO: 4.03 )
MDSO' s 10-Year Interest Coverage Range
Min: 4.03   Max: 9999.99
Current: 4.03

4.03
9999.99
F-Score: 5
Z-Score: 5.62
M-Score: -2.31
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 2.96
MDSO's Operating margin (%) is ranked higher than
65% of the 2062 Companies
in the Global Health Information Services industry.

( Industry Median: 5.48 vs. MDSO: 2.96 )
MDSO' s 10-Year Operating margin (%) Range
Min: -36.17   Max: 14
Current: 2.96

-36.17
14
Net-margin (%) 0.38
MDSO's Net-margin (%) is ranked higher than
60% of the 2062 Companies
in the Global Health Information Services industry.

( Industry Median: 3.74 vs. MDSO: 0.38 )
MDSO' s 10-Year Net-margin (%) Range
Min: -52.41   Max: 21.36
Current: 0.38

-52.41
21.36
ROE (%) 0.53
MDSO's ROE (%) is ranked higher than
59% of the 2001 Companies
in the Global Health Information Services industry.

( Industry Median: 7.10 vs. MDSO: 0.53 )
MDSO' s 10-Year ROE (%) Range
Min: 9.06   Max: 63.95
Current: 0.53

9.06
63.95
ROA (%) 0.22
MDSO's ROA (%) is ranked higher than
60% of the 2086 Companies
in the Global Health Information Services industry.

( Industry Median: 3.75 vs. MDSO: 0.22 )
MDSO' s 10-Year ROA (%) Range
Min: -106.4   Max: 22.66
Current: 0.22

-106.4
22.66
ROC (Joel Greenblatt) (%) 24.99
MDSO's ROC (Joel Greenblatt) (%) is ranked higher than
71% of the 2071 Companies
in the Global Health Information Services industry.

( Industry Median: 28.79 vs. MDSO: 24.99 )
MDSO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -324.06   Max: 274.82
Current: 24.99

-324.06
274.82
Revenue Growth (3Y)(%) 14.00
MDSO's Revenue Growth (3Y)(%) is ranked higher than
85% of the 1669 Companies
in the Global Health Information Services industry.

( Industry Median: 5.60 vs. MDSO: 14.00 )
MDSO' s 10-Year Revenue Growth (3Y)(%) Range
Min: -21.7   Max: 14
Current: 14

-21.7
14
EBITDA Growth (3Y)(%) -5.60
MDSO's EBITDA Growth (3Y)(%) is ranked higher than
62% of the 1370 Companies
in the Global Health Information Services industry.

( Industry Median: 7.20 vs. MDSO: -5.60 )
MDSO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 14.7
Current: -5.6

0
14.7
» MDSO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

MDSO Guru Trades in Q4 2013

Ron Baron 121,000 sh (New)
Columbia Wanger 443,000 sh (New)
Jim Simons 60,094 sh (New)
Chuck Royce 41,700 sh (+4.25%)
Mariko Gordon Sold Out
Steven Cohen Sold Out
» More
Q1 2014

MDSO Guru Trades in Q1 2014

Steven Cohen 102,820 sh (New)
Ron Baron 518,040 sh (+328.13%)
Columbia Wanger 662,500 sh (+49.55%)
Jim Simons 80,669 sh (+34.24%)
Chuck Royce 40,000 sh (-4.08%)
» More
Q2 2014

MDSO Guru Trades in Q2 2014

George Soros 126,666 sh (New)
Frank Sands 4,720,008 sh (New)
Columbia Wanger 1,360,500 sh (+105.36%)
Chuck Royce 40,000 sh (unchged)
Steven Cohen 47,400 sh (unchged)
Jim Simons Sold Out
Ron Baron 230,635 sh (-55.48%)
» More
Q3 2014

MDSO Guru Trades in Q3 2014

Columbia Wanger 1,793,500 sh (+31.83%)
Frank Sands 4,866,217 sh (+3.1%)
Chuck Royce 40,000 sh (unchged)
Steven Cohen Sold Out
Ron Baron 193,346 sh (-16.17%)
George Soros 6,666 sh (-94.74%)
» More
» Details

Insider Trades

Latest Guru Trades with MDSO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-09-30 Reduce -94.74%0.04%$38.61 - $49.49 $ 46.786%6666
Frank Sands 2014-06-30 New Buy0.51%$33.98 - $58.27 $ 46.7813%4720008
Ron Baron 2014-06-30 Reduce -55.48%0.06%$33.98 - $58.27 $ 46.7813%230635
George Soros 2014-06-30 New Buy0.04%$33.98 - $58.27 $ 46.7813%126666
Ron Baron 2014-03-31 Add 328.13%0.08%$51.84 - $67.54 $ 46.78-23%518040
Ron Baron 2013-12-31 New Buy0.03%$43.03 - $61.755 $ 46.78-16%121000
Mariko Gordon 2013-12-31 Sold Out 0.02%$43.03 - $61.755 $ 46.78-16%0
Mariko Gordon 2013-09-30 New Buy0.02%$36.86 - $50.41 $ 46.786%3640
Joel Greenblatt 2012-12-31 Sold Out 0.04%$18.69 - $21.43 $ 46.78135%0
Joel Greenblatt 2012-06-30 Reduce -51.69%0.04%$12.28 - $16.34 $ 46.78240%16667
Joel Greenblatt 2012-03-31 Reduce -27.73%0.04%$9.31 - $13.83 $ 46.78353%34499
Joel Greenblatt 2011-09-30 Add 310.24%0.09%$7.27 - $12.24 $ 46.78405%45007
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 2339.00
MDSO's P/E(ttm) is ranked higher than
64% of the 2271 Companies
in the Global Health Information Services industry.

( Industry Median: 58.20 vs. MDSO: 2339.00 )
MDSO' s 10-Year P/E(ttm) Range
Min: 11.44   Max: 2448.5
Current: 2339

11.44
2448.5
P/B 10.15
MDSO's P/B is ranked higher than
52% of the 2271 Companies
in the Global Health Information Services industry.

( Industry Median: 3.38 vs. MDSO: 10.15 )
MDSO' s 10-Year P/B Range
Min: 4.53   Max: 28.83
Current: 10.15

4.53
28.83
P/S 7.96
MDSO's P/S is ranked higher than
53% of the 2271 Companies
in the Global Health Information Services industry.

( Industry Median: 2.60 vs. MDSO: 7.96 )
MDSO' s 10-Year P/S Range
Min: 1.31   Max: 12.62
Current: 7.96

1.31
12.62
PFCF 75.45
MDSO's PFCF is ranked higher than
73% of the 2271 Companies
in the Global Health Information Services industry.

( Industry Median: 84.60 vs. MDSO: 75.45 )
MDSO' s 10-Year PFCF Range
Min: 12.91   Max: 276.85
Current: 75.45

12.91
276.85
EV-to-EBIT 267.91
MDSO's EV-to-EBIT is ranked higher than
63% of the 2271 Companies
in the Global Health Information Services industry.

( Industry Median: 34.56 vs. MDSO: 267.91 )
MDSO' s 10-Year EV-to-EBIT Range
Min: 8.8   Max: 381.8
Current: 267.91

8.8
381.8
PEG 508.48
MDSO's PEG is ranked higher than
82% of the 2271 Companies
in the Global Health Information Services industry.

( Industry Median: 9999.00 vs. MDSO: 508.48 )
MDSO' s 10-Year PEG Range
Min: 7.91   Max: 209.64
Current: 508.48

7.91
209.64
Shiller P/E 150.27
MDSO's Shiller P/E is ranked higher than
78% of the 2271 Companies
in the Global Health Information Services industry.

( Industry Median: 9999.00 vs. MDSO: 150.27 )
MDSO' s 10-Year Shiller P/E Range
Min: 126.29   Max: 6000
Current: 150.27

126.29
6000
Current Ratio 3.95
MDSO's Current Ratio is ranked higher than
88% of the 2043 Companies
in the Global Health Information Services industry.

( Industry Median: 1.91 vs. MDSO: 3.95 )
MDSO' s 10-Year Current Ratio Range
Min: 0.44   Max: 5.35
Current: 3.95

0.44
5.35
Quick Ratio 3.95
MDSO's Quick Ratio is ranked higher than
89% of the 2043 Companies
in the Global Health Information Services industry.

( Industry Median: 1.78 vs. MDSO: 3.95 )
MDSO' s 10-Year Quick Ratio Range
Min: 0.44   Max: 5.35
Current: 3.95

0.44
5.35

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 10.83
MDSO's Price/Tangible Book is ranked higher than
64% of the 2271 Companies
in the Global Health Information Services industry.

( Industry Median: 8.40 vs. MDSO: 10.83 )
MDSO' s 10-Year Price/Tangible Book Range
Min: 6.32   Max: 151.5
Current: 10.83

6.32
151.5
Price/DCF (Projected) 6.61
MDSO's Price/DCF (Projected) is ranked higher than
74% of the 2271 Companies
in the Global Health Information Services industry.

( Industry Median: 8.40 vs. MDSO: 6.61 )
MDSO' s 10-Year Price/DCF (Projected) Range
Min: 4.85   Max: 10.1
Current: 6.61

4.85
10.1
Price/Median PS Value 2.21
MDSO's Price/Median PS Value is ranked higher than
53% of the 2271 Companies
in the Global Health Information Services industry.

( Industry Median: 1.18 vs. MDSO: 2.21 )
MDSO' s 10-Year Price/Median PS Value Range
Min: 0.37   Max: 3.28
Current: 2.21

0.37
3.28
Price/Graham Number 31.61
MDSO's Price/Graham Number is ranked higher than
69% of the 2271 Companies
in the Global Health Information Services industry.

( Industry Median: 27.59 vs. MDSO: 31.61 )
MDSO' s 10-Year Price/Graham Number Range
Min: 1.91   Max: 29.93
Current: 31.61

1.91
29.93
Earnings Yield (Greenblatt) 0.40
MDSO's Earnings Yield (Greenblatt) is ranked higher than
60% of the 2056 Companies
in the Global Health Information Services industry.

( Industry Median: 3.80 vs. MDSO: 0.40 )
MDSO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 11.3
Current: 0.4

0.3
11.3
Forward Rate of Return (Yacktman) -0.89
MDSO's Forward Rate of Return (Yacktman) is ranked higher than
59% of the 1069 Companies
in the Global Health Information Services industry.

( Industry Median: 13.07 vs. MDSO: -0.89 )
MDSO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -0.9   Max: 21.2
Current: -0.89

-0.9
21.2

Business Description

Industry: Application Software » Health Information Services
Compare: » details
Traded in other countries:2M9.Germany,
Medidata Solutions, Inc., was incorporated in June 1999and reincorporated in the State of Delaware in May 2000. The Company is a provider of cloud-based solutions for clinical research in life sciences, designed to transform clinical development and increase the value of the customers' research investments. Medidata's solutions are designed to address the underlying requirements of clinical development, rather than just its current processes, to maximize the value of the overall research process. Its cloud-based solutions, metrics and services allow users to accurately and efficiently design clinical trials; manage and monitor ongoing trial activities; develop and administer trial budgets; capture, manage and report clinical trial data; plan and execute randomized subject allocation methodologies; manage and allocate clinical trial supplies; and view, track, and evaluate trial progress through easy-to-use, Internet-enabled platforms. The Company compete with firms such as Oracle, Perceptive Informatics and others offering products and services that compete with one or more of the solutions. It competes on the basis of several factors, including, breadth and depth of solution offerings; platform capabilities, including interoperability; ease of use of solutions and rates of user adoption; solution functionality and flexibility; analytics and benchmarking; speed and performance required to enable customers to access clinical trial data in real-time; product reliability and scalability; infrastructure accessibility and security; regulatory compliance; financial stability; commercial and technology partnerships; depth of expertise and quality of professional services and customer support on a global basis; and sales and marketing capabilities, including the ability to create and communicate operational value. The Company has registered trademarks and service marks in the United States and abroad, and filed applications for the registration of additional trademarks and service marks. The principal trademarks are "Medidata," "Medidata Clinical Cloud," "Medidata Patient Cloud," "Medidata CRO Contractor," "Medidata Designer," "Medidata Grants Manager," "Medidata Rave," "Medidata Balance," "Medidata Coder," and "Medidata Insights." It also holds several domain names, including the domain names "mdsol.com" and "medidatasolutions.com". The use of Company's software products, services and hosted solutions by customers engaged in clinical trials must be done in a manner that is compliant with a complex array of United States federal and state laws and regulations, including regulation by the Food and Drug Administration, as well as regulations and guidance issued by foreign governments and international non-governmental organizations.
» More Articles for MDSO

Headlines

Articles On GuruFocus.com
Medidata: SaaS Business Model Leveraging Growth Of The Company Oct 23 2014 
Frank Sands Adds 5 New Stocks Aug 14 2014 
Medidata Solutions: Benefit from Growing Cloud Applications with This Stock May 27 2014 
Medidata Solutions : A SAAS Provider For Your Portfolio Mar 23 2014 
Medidata Solutions Inc. (MDSO) Chairman & CEO Tarek Sherif sells 8,667 Shares Mar 08 2011 
Medidata Solutions Inc. (MDSO) Chairman & CEO Tarek Sherif sells 8,000 Shares Mar 03 2011 
Medidata Solutions Inc. (MDSO) Chairman & CEO Tarek Sherif sells 13,667 Shares Feb 07 2011 
Medidata Solutions Inc. (MDSO) Chairman & CEO Tarek Sherif sells 3,000 Shares Feb 03 2011 
Medidata Solutions Inc. (MDSO) Chairman & CEO Tarek Sherif sells 13,667 Shares Jan 10 2011 
Medidata Solutions Inc. (MDSO) Chairman & CEO Tarek Sherif sells 3,000 Shares Jan 05 2011 

More From Other Websites
Medidata Announces Availability of Patient Profiles Offering Dec 10 2014
Medidata Announces Availability of Patient Profiles Offering Dec 10 2014
Vital Connect Partners with Medidata to Enhance Clinical Trials with Continuous Vital Sign... Dec 09 2014
Next Week Dec 06 2014
Veeva Stock Jumps After Q3 Earnings, Guidance Beat Nov 26 2014
Medidata to Host Financial Analyst Day in New York City on December 8 Nov 24 2014
Medidata to Host Financial Analyst Day in New York City on December 8 Nov 24 2014
Medidata and TransCelerate BioPharma Inc. Announce Findings of Joint Research Initiative on Clinical... Nov 19 2014
Medidata and TransCelerate BioPharma Inc. Announce Findings of Joint Research Initiative on Clinical... Nov 19 2014
Good News From A Failed Digital Health Randomized Clinical Trial: It Was Performed Nov 18 2014
Medidata Collaborates with GlaxoSmithKline on Mobile Health Initiative to Test Novel Technology for... Nov 17 2014
Medidata Collaborates with GlaxoSmithKline on Mobile Health Initiative to Test Novel Technology for... Nov 17 2014
Medidata Collaborates with GlaxoSmithKline on Mobile Health Initiative to Test Novel Technology for... Nov 17 2014
MEDIDATA SOLUTIONS, INC. Financials Nov 14 2014
Medidata Selected by ASLAN Pharmaceuticals as Enterprise-Wide Technology Platform for Enhancing... Nov 14 2014
Medidata and PPD Partner to Offer New Approach to Risk-Based Monitoring Nov 14 2014
Medidata Teams up with Mundipharma Research to Move Clinical Research to the Cloud Nov 14 2014
Medidata Reports Record Third Quarter 2014 Revenues Nov 14 2014
Medidata to Participate in U.S. Trade Mission to Japan and South Korea, Supporting Stronger Economic... Nov 14 2014
10-Q for Medidata Solutions, Inc. Nov 09 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK